Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - Pharmaceutical News - Data from Stanford University Advance Knowledge in Biosimilars (Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review) - November 20, 2017

Pharmacy News Article

 9/13/17 - Data from Stanford University Advance Knowledge in Biosimilars (Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review)

By a News Reporter-Staff News Editor at Biotech Week Investigators discuss new findings in Drugs and Therapies - Biosimilars. According to news reporting originating in Portola Valley, California, by NewsRx journalists, research stated, "A systematic review was conducted to explore the immunogenicity of biologic agents across inflammatory diseases and its potential impact on efficacy/safety. Literature searches were conducted through November 2016 to identify controlled and observational studies of biologics/biosimilars administered for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), psoriasis (Ps), Crohn's disease, and ulcerative colitis."

Financial support for this research came from Pfizer (see also Drugs and Therapies - Biosimilars).

The news reporters obtained a quote from the research from Stanford University, "Of > 21,000 screened publications, 443 were included. Anti-drug antibody (ADAb) rates varied widely among biologics across diseases (and are not directly comparable because of immunoassay heterogeneity); the highest overall rates were reported with infliximab (0-83%), adalimumab (0-54%), and infliximab biosimilar CT-P13 (21-52%), and the lowest with secukinumab (0-1%), ustekinumab (1-11%), etanercept (0-13%), and golimumab (0-19%). Most ADAbs were neutralizing, except those to abatacept and etanercept. ADAb+ versus ADAb- patients had lower rates of clinical response to adalimumab (RA, PsA, JIA, AS, Ps), golimumab (RA), infliximab (RA, PsA, AS, Ps), rituximab (RA), ustekinumab (Ps), and CT-P13 (RA, AS). Higher rates of infusion-related reactions were reported in infliximab- and CT-P13-treated ADAb+ patients. Background immunosuppressives/anti-proliferatives reduced biologic immunogenicity across diseases. Based on reviewed reports, biologic/biosimilar immunogenicity differs among agents, with the highest rates observed with infliximab and adalimumab."

According to the news reporters, the research concluded: "As ADAb formation in biologic-/biosimilar-treated patients may increase the risk of lost response, the immunogenicity of these agents is an important (albeit not the only) consideration in the treatment decision-making process."

For more information on this research see: Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. Biodrugs, 2017;31(4):299-316. Biodrugs can be contacted at: Adis Int Ltd, 5 The Warehouse Way, Northcote 0627, Auckland, New Zealand.

Our news correspondents report that additional information may be obtained by contacting V. Strand, Stanford University, Div Immunol Rheumatol, Sch Med, Portola Valley, CA 94028, United States. Additional authors for this research include A. Balsa, J. Al-Saleh, L. Barile-Fabris, T. Horiuchi, T. Takeuchi, S. Lula, C. Hawes, B. Kola and L. Marshall.

Keywords for this news article include: Portola Valley, California, United States, North and Central America, Musculoskeletal Diseases and Conditions, Ankylosing Spondylitis, Article Review, Tumor Necrosis Factor (TNF) Inhibitors, Autoimmune Diseases and Conditions, Genetically-Engineered Proteins, Joint Diseases and Conditions, Monoclonal Antibodies, Rheumatoid Arthritis, Genetic Engineering, Drugs and Therapies, Immunologic Agents, Pharmaceuticals, Bioengineering, Antirheumatics, Biotechnology, Immunotherapy, Biosimilars, Adalimumab, Infliximab, Biologics, Golimumab, Stanford University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 20: Obesity Management: Overview of Pharmacotherapy
Last Chance
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement